Literature DB >> 20302583

Mechanisms of the sensory effects of tacrolimus on the skin.

U Pereira1, N Boulais, N Lebonvallet, J P Pennec, G Dorange, L Misery.   

Abstract

BACKGROUND: Tacrolimus is an immunosuppressant drug currently used for the treatment of atopic dermatitis and pruritus. This topical therapy is effective and safe, but transient burning, stinging and itch are frequently reported.
OBJECTIVES: To understand the mechanisms underlying these burning sensations.
METHODS: We examined the impact of tacrolimus on substance P (SP) release in an in vitro model of cutaneous neurogenic inflammation. Because phosphorylation of TRPV1 (transient receptor potential subtype vanilloid 1) plays a role in the induction of pain, we investigated whether tacrolimus regulates the phosphorylation state of TRPV1. Finally, we used a macropatch to evaluate the impact of tacrolimus on voltage-gated calcium currents of sensory neurons.
RESULTS: Tacrolimus was able to induce initial SP release by extracellular calcium influx and inhibited SP release induced by capsaicin after 1, 24 and 72 h of pretreatment. Analysis of TRPV1 phosphorylation by Western blot confirmed the capacity of tacrolimus to favour phosphorylation. An electrophysiological study showed inhibitory effects on calcium currents.
CONCLUSIONS: The efficacy of tacrolimus in pruritus, as well as the sensory side-effects, could be explained by a direct effect on neurons through an effect on calcineurin, possibly by a desensitization of TRPV1 and calcium currents through the PIP(2) regulation pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20302583     DOI: 10.1111/j.1365-2133.2010.09757.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Therapeutic perspectives in atopic dermatitis.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

Review 2.  Atopic dermatitis and the nervous system.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

Review 3.  Topical therapies for pruritus.

Authors:  Sarina B Elmariah; Ethan A Lerner
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 4.  Therapy of pruritus.

Authors:  Tejesh Patel; Gil Yosipovitch
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

5.  FK506 (tacrolimus) causes pain sensation through the activation of transient receptor potential ankyrin 1 (TRPA1) channels.

Authors:  Tomo Kita; Kunitoshi Uchida; Kenichi Kato; Yoshiro Suzuki; Makoto Tominaga; Jun Yamazaki
Journal:  J Physiol Sci       Date:  2018-11-26       Impact factor: 2.781

6.  Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis.

Authors:  Bodi Zhang; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Shahrzad Asadi; Nikolaos Sismanopoulos; Danae-Anastasia Delivanis; Zuyi Weng; Alexandra Miniati; Magdalini Vasiadi; Alexandra Katsarou-Katsari; Benchun Miao; Susan E Leeman; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Allergy Clin Immunol       Date:  2011-03-31       Impact factor: 10.793

7.  The Immunosuppressant Macrolide Tacrolimus Activates Cold-Sensing TRPM8 Channels.

Authors:  José Miguel Arcas; Alejandro González; Katharina Gers-Barlag; Omar González-González; Federico Bech; Lusine Demirkhanyan; Eleonora Zakharian; Carlos Belmonte; Ana Gomis; Félix Viana
Journal:  J Neurosci       Date:  2018-12-13       Impact factor: 6.167

Review 8.  Targeted treatment of pruritus: a look into the future.

Authors:  H L Tey; G Yosipovitch
Journal:  Br J Dermatol       Date:  2011-05-30       Impact factor: 9.302

Review 9.  The itchy scalp--scratching for an explanation.

Authors:  Ghada A Bin Saif; Marna E Ericson; Gil Yosipovitch
Journal:  Exp Dermatol       Date:  2011-12       Impact factor: 3.960

Review 10.  Neuropathic pruritus.

Authors:  Laurent Misery; Emilie Brenaut; Raphaële Le Garrec; Claire Abasq; Steeve Genestet; Pascale Marcorelles; Fabien Zagnoli
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.